GeneTether is a precision gene editing company developing high efficiency gene therapies to treat human disease.

Developed and teaching Biochemistry and a literature based course on Stem Cell Biology, Research, and Development. Developed, produced, and teaching the UC Berkeley Extension online Introductory Biochemistry course.

Onconetics is developing personalized cancer treatments.

My research interests include the differentiation of pluripotent stem cells into thyroid and parathyroid tissues, the biology of head & neck cancers, developing Crispr/Cas9 and TALEN gene therapies, DNA damage and repair in pluripotent stem cell lines and cancer cells.

Establishing research programs investigating DNA damage and repair in pluripotent stem cell lines and the biology of head & neck cancers. Co-Director of Molecular Biology Core for UCSF Program Project Grant “Development of iPS Cells for Treatment of Hemoglobinopathies”.

Lecturer Senior Biochemistry 4413 and Intro Chemistry Lab 1103 (2010 academic year).

EGCELL Scientific was an early stage biotechnology company commercializing a novel human pluripotent stem cell platform for drug discovery and toxicology screening.•Directed R&D for commercialization of pluripotent stem cells and raised funds for company financing.

The CPMCRI is a nonprofit research institute of the California Pacific Medical Center/Sutter Health.•Established a hES/iPS cell culture program focused on directed differentiation of hES/iPS cells, hES/iPS cell genomic stability, and gene modification technologies to generate transgenic and knockout hES/iPS cell lines

ACT is a publicly traded biotechnology company developing regenerative medicine therapeutic products from human embryonic stem cells and commercializing human embryonic stem cell technologies.•Research Director Alameda Molecular Biology Group•Opened the ACT Alameda facility and recruited and managed scientific staff•Developed solutions for scale up, growth and large scale maintenance of human embryonic stem cell and differentiated cell cultures•Led scientific group for gene expression analysis of over 180 cell lines differentiated from 2 human embryonic stem cell lines using gene chips, qPCR, and miRNA analysis of human embryonic and differentiated cell lines•Developed gene knockout and transgenic technologies to engineer human embryonic stem cells and differentiated cell lines•Commercialized human embryonic stem cell technologies developed from the Advanced Cell Technology ACTCellerate platform•Managed outside academic and commercial R&D programs and collaborations•Co-authored 14 CIRM grant applications (1 Training Grant, 3 Seed Grants, 7 Comprehensive Grants, 1 Facilities Grant, 2 New hES Cell Grants) of which 2 were awarded (UCSB hES Cell Training Grant and Randall Lee, MD, UCSF Comprehensive Grant)•Managed the transfer of ACT technology to Embryome Sciences and decommissioning and closure of the ACT Alameda facility in 2008

Biotechnology and Scientific consulant for companies in the San Francisco Bay area and Houston, Texas, including: DiscoverX, DNAtriX, Inverseon, and Advanced Cell Technology.

Pangene developed & commercialized genomics platform applications & DNA damage repair drugs for the treatment of cancer.•Directed Transgenics and Cell Engineering programs•Designed & managed milestone driven research collaborations for the genetic modification of corn & animals.•Negotiated option agreements with corporate partners to out-license proprietary technologies.•Directed & recruited genomics services group of 30 scientists & research associates for rapid cDNA cloning, genomic DNA cloning, & cell engineering with over $5M revenues & licensing fees.•Directed Oncology Diagnostics and Therapeutic Products group.•Directed preclinical development of cancer diagnostic & therapeutic products.•Senior Scientist•Invented a novel recombinase based genomic DNA cloning process.•Developed recombinase based rapid cDNA cloning kit and services.•Successfully competed for an investigator initiated 5-year NIEHS grant to investigate mechanisms of double strand break repair, site-specific DNA strand breaks, & nucleotide excision repair in mammalian cells.•Managed decommissioning and closure of Pangene facility fall 2003.